NCT00952705 - A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age | Biotech Hunter

Enrollment

1,800

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

March 31, 2010

Conditions

Healthy or Stable Underlying Chronic Medical Condition

Interventions

BIOLOGICAL

Q/LAIV-BFS (MEDI8662)

A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.

BIOLOGICAL

FluMist/B/Yamagata

FluMist/B/Yamagata - 0.2 mL dose at Day 0

BIOLOGICAL

FluMist/B/Victoria

FluMist/B/Victoria - 0.2 mL dose at Day 0

Trial Locations (18)

13760

Regional Clinical Research, Endwell

14609

Rochester Clinical Research Inc., Rochester

29464

Palmetto Medical Research, Mt. Pleasant

30281

Clinical Research Atlanta, Stockbridge

32720

Avail Clinical Research, LLC, DeLand

33143

Miami Research Associates, Miami

33761

Tampa Bay Medical Research, Inc., Clearwater

36608

Coastal Clinical Research, Inc., Mobile

63141

Sundance Clinical Research, St Louis

66212

Vince and Associates Clinical Research, Overland Park

66219

Johnson County Clin-Trials, Lenexa

68134

Meridian Clinical Research, LLC, Omaha

70006

Benchmark Research, Metairie

76135

Benchmark Research Ft. Worth, Fort Worth

78705

Benchmark Research Austin, Austin

94102

Benchmark Research, San Francisco

95816

Benchmark Research, Sacramento

92103-6204

California Research Foundation, San Diego